By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

IDM Pharma, Inc. 

5820 Nancy Ridge Drive

San Diego  California  92121  U.S.A.
Phone: 858-860-2500 Fax: 858-860-2600


SEARCH JOBS








Company News
Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Completes Acquisition of IDM Pharma, Inc. (IDMI) 6/25/2009 9:50:55 AM
Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Announces Completion of Tender Offer for All Outstanding Shares of IDM Pharma, Inc. (IDMI) 6/23/2009 9:34:04 AM
Takeda Pharmaceutical Co. Ltd. (TKDG.DE) to Acquire IDM Pharma, Inc. (IDMI) for $75 Million, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise 5/18/2009 7:35:11 AM
IDM Pharma, Inc. (IDMI) Reports First Quarter Financial Results 5/11/2009 8:24:17 AM
IDM Pharma, Inc. (IDMI) Receives The Nasdaq Stock Market -- New York Shareholder Equity Notification 4/14/2009 8:51:15 AM
IDM Pharma, Inc. (IDMI) Complies With NASDAQ Marketplace Rule 4350(b)(1)(B) and Announces Filing of Annual Report on Form 10-K for 2008 Fiscal Year Containing Audit Opinion With Going Concern Qualification 4/3/2009 8:29:46 AM
IDM Pharma, Inc. (IDMI) Reports 2008 Financial Results 3/31/2009 9:15:14 AM
IDM Pharma, Inc. (IDMI)'s MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 3/9/2009 10:17:12 AM
IDM Pharma, Inc. (IDMI) Provides Update on Mifamurtide (MEPACT(R), L-MTP-PE) European Regulatory Status Positive Opinion Formally Adopted by CHMP 12/19/2008 10:37:07 AM
IDM Pharma, Inc. (IDMI) Receives Recommendation for Approval of Mifamurtide for the Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma in Europe from the Committee for Medicinal Products for Human Use 11/18/2008 6:18:20 AM
123456789
//-->